Axogen Inc. (AXGN) 2.36 $AXGN
AxoGen, Inc. to Report Second Quarter Financial Results on August 4, 2014
GlobeNewswire - Wed Jul 16, 3:52AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the second quarter ended June 30, 2014 on Monday, August 4, 2014 after the close of the markets.
AxoGen, Inc. To Present Nerve Repair Data at 2014 Federation of European Societies for Surgery of the Hand (FESSH) International Congress
GlobeNewswire - Wed Jun 18, 4:34AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, today announced the acceptance of two clinical presentations on the use of Avance(R) Nerve Graft and a scientific presentation on the use of coaptation aids in nerve repair at the 29th Congress of the Federation of European Societies for Surgery of the Hand (FESSH), June 18-21, 2014 in Paris, France. In addition, the Company will be exhibiting its full portfolio of nerve repair products at FESSH Booth 35.
AxoGen, Inc. on Preliminary List of Additions to Russell Microcap(R) Index
GlobeNewswire - Mon Jun 16, 6:10AM CDT
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company focused on the $1.6 billion US peripheral nerve repair market, announced today that it was included on a preliminary list of additions to the Russell Microcap(R) Index according to information posted by Russell Investments on June 13, 2014. The final 2014 reconstitution of the Russell Indexes will take place after the market closes on June 27, 2014 and final membership lists will be posted on June 30, 2014, with trading in the reconstituted indexes commencing that same day.
AxoGen, Inc. to Present at JMP Securities Healthcare Conference
GlobeNewswire - Mon Jun 09, 6:12AM CDT
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company focused on the $1.6 billion US peripheral nerve repair market, is scheduled to present at the 9th Annual JMP Securities Healthcare Conference on Tuesday, June 24, 2014 at 12:30pm (ET) at the Westin New York Grand Central.
AxoGen, Inc. Receives Department of Defense Funding for Next Generation Peripheral Nerve Repair Research
GlobeNewswire - Wed Jun 04, 6:13AM CDT
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), the emerging leader of the $1.6 billion U.S. peripheral nerve repair market, announced today that it would share in the award of two Department of Defense Grants totaling approximately $1.9 million with Brigham and Women's Hospital in Boston (BWH).
AxoGen, Inc. to Exhibit Nerve Repair Portfolio at American Academy of Orthopedic Surgeons 2014 Annual Meeting
GlobeNewswire - Wed Mar 12, 6:02AM CDT
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), the emerging leader of the $1.6 billion U.S. peripheral nerve repair market, is pleased to announce its participation at the American Academy of Orthopedic Surgeons (AAOS) 2014 Annual Meeting, March 11-15, 2014 at the Morial Convention Center in New Orleans, LA, Booth 5818.
AxoGen, Inc. Reports 46% Fourth Quarter and 42% Full Year 2013 Revenue Growth
GlobeNewswire - Fri Mar 07, 2:59AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the emerging leader of the $1.6 billion U.S. peripheral nerve repair market, announced financial results for the fourth quarter and full year ended December 31, 2013. Revenue for the quarter grew 46% to $3.0 million and for the year grew 42% to $10.9 million as compared to comparable periods.
AxoGen, Inc. to Present at Canaccord Genuity Musculoskeletal Conference
GlobeNewswire - Mon Mar 03, 6:03AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the only company completely focused on peripheral nerve repair, is scheduled to present at the 9th Annual Canaccord Genuity Musculoskeletal Conference on Tuesday, March 11, 2014 at 11:10am CT (12:10pm ET) at the Sheraton New Orleans Hotel.
AxoGen, Inc. to Report Fourth Quarter and Full Year 2013 Financial Results on March 6, 2014
GlobeNewswire - Wed Feb 12, 6:04AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the only company completely focused on peripheral nerve repair, will report results for the fourth quarter and full year ended December 31, 2013 on Thursday, March 6, 2014 after the market closes.
AxoGen, Inc. Announces Presentation of New Clinical Data For Avance(R) Nerve Graft
GlobeNewswire - Thu Feb 06, 6:03AM CST
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), the only company completely focused on peripheral nerve repair, today announced that new data from the CHANGE Study and the Ranger(R) Study was presented by study investigators at the recent combined annual meetings of the American Association for Hand Surgery (AAHS), American Society for Peripheral Nerve (ASPN) and American Society for Reconstructive Microsurgery (ASRM).
AxoGen, Inc. Gives Presentation on Nerve Repair Science at International Conference
GlobeNewswire - Fri Jan 24, 6:03AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the only medical products company completely focused on peripheral nerve repair, today announced the acceptance of a scientific presentation on nerve repair at the International Symposium on Peripheral Nerve Regeneration (ISPNR) 2014 Meeting. The symposium, being held in Torino, Italy, acts as a platform for presenting and discussing new developments in the field of nerve regeneration and tissue engineering and attracts clinicians and researchers from across the globe.
AxoGen, Inc. to Present at Noble Financial Capital Markets' Tenth Annual Equity Conference
GlobeNewswire - Tue Jan 21, 6:03AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the only medical products company completely focused on peripheral nerve repair, today announced that Greg Freitag, AxoGen's Chief Financial Officer and General Counsel, is scheduled to present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida on Wednesday, January 22, 2014 at 8:30 am ET.
Insureon CEO: Technology Investments Key to Acquisition Target Insurance Noodle
Fran Lysiak - AMBest - Fri Jan 10, 3:44PM CST
Insureon, an online commercial insurance broker and technology company, has agreed to acquire Insurance Noodle, the online wholesale broker and subsidiary of Willis Group Holdings.
Gerald Commissiong, CEO of Amarantus to Participate in Twitter Chat, "The Human Brain"
GlobeNewswire - Thu Jan 09, 2:58PM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that the Company's President and CEO, Gerald E. Commissiong will participate in a Twitter chat tonight at 9:00 PM ET on the topic, "The Human Brain."
AxoGen, Inc. to Sponsor "Current Concepts for Improving Nerve Repair Outcomes" at the American Association for Hand Surgery (AAHS) Annual Meeting
GlobeNewswire - Thu Jan 09, 6:02AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the only regenerative medicine company completely focused on peripheral nerve repair, today announced that it will sponsor a lunch symposium and panel discussion at the combined annual meetings of the American Association for Hand Surgery (AAHS), American Society for Peripheral Nerve (ASPN) and American Society for Reconstructive Microsurgery (ASRM) taking place January 8-14, 2014 in Kauai, Hawaii.
AxoGen Receives Product Innovation Leadership Award from Frost & Sullivan
GlobeNewswire - Mon Jan 06, 1:32PM CST
via PRWEB - AxoGen, Inc. (NASDAQ:AXGN), the only regenerative medicine company completely focused on peripheral nerve repair, has been awarded the 2014 North American New Product Innovation Leadership Award for Peripheral Nerve Repair by the preeminent global research organization, Frost & Sullivan. The award is based on the findings of Frost & Sullivan's Best Practices Research Team which studied the nearly one million peripheral nerve injury repair procedures performed every year in the United States and recognized AxoGen for developing and commercializing the Avance(R) Nerve Graft.
Frost & Sullivan Applaud AxoGen's Proprietary Process for Producing Decellularized Nerve Allografts
PR Newswire Europe - Mon Jan 06, 6:45AM CST
-- AxoGen is the only regenerative medicine company that is completely focused on peripheral nerve repair
Nasdaq stocks posting largest volume increases
AP - Thu Jan 02, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
AxoGen (AXGN) in Focus: Stock Surges 25.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 8:46AM CST
AxoGen was a big mover last session, with shares rising over 25%.
AxoGen, Inc. to Report Second Quarter Financial Results on August 4, 2014
GlobeNewswire - Wed Jul 16, 3:52AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the second quarter ended June 30, 2014 on Monday, August 4, 2014 after the close of the markets.
AxoGen, Inc. To Present Nerve Repair Data at 2014 Federation of European Societies for Surgery of the Hand (FESSH) International Congress
GlobeNewswire - Wed Jun 18, 4:34AM CDT
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, today announced the acceptance of two clinical presentations on the use of Avance(R) Nerve Graft and a scientific presentation on the use of coaptation aids in nerve repair at the 29th Congress of the Federation of European Societies for Surgery of the Hand (FESSH), June 18-21, 2014 in Paris, France. In addition, the Company will be exhibiting its full portfolio of nerve repair products at FESSH Booth 35.
AxoGen, Inc. on Preliminary List of Additions to Russell Microcap(R) Index
GlobeNewswire - Mon Jun 16, 6:10AM CDT
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company focused on the $1.6 billion US peripheral nerve repair market, announced today that it was included on a preliminary list of additions to the Russell Microcap(R) Index according to information posted by Russell Investments on June 13, 2014. The final 2014 reconstitution of the Russell Indexes will take place after the market closes on June 27, 2014 and final membership lists will be posted on June 30, 2014, with trading in the reconstituted indexes commencing that same day.
AxoGen, Inc. to Present at JMP Securities Healthcare Conference
GlobeNewswire - Mon Jun 09, 6:12AM CDT
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company focused on the $1.6 billion US peripheral nerve repair market, is scheduled to present at the 9th Annual JMP Securities Healthcare Conference on Tuesday, June 24, 2014 at 12:30pm (ET) at the Westin New York Grand Central.
AxoGen, Inc. Receives Department of Defense Funding for Next Generation Peripheral Nerve Repair Research
GlobeNewswire - Wed Jun 04, 6:13AM CDT
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), the emerging leader of the $1.6 billion U.S. peripheral nerve repair market, announced today that it would share in the award of two Department of Defense Grants totaling approximately $1.9 million with Brigham and Women's Hospital in Boston (BWH).
AxoGen, Inc. to Exhibit Nerve Repair Portfolio at American Academy of Orthopedic Surgeons 2014 Annual Meeting
GlobeNewswire - Wed Mar 12, 6:02AM CDT
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), the emerging leader of the $1.6 billion U.S. peripheral nerve repair market, is pleased to announce its participation at the American Academy of Orthopedic Surgeons (AAOS) 2014 Annual Meeting, March 11-15, 2014 at the Morial Convention Center in New Orleans, LA, Booth 5818.
AxoGen, Inc. Reports 46% Fourth Quarter and 42% Full Year 2013 Revenue Growth
GlobeNewswire - Fri Mar 07, 2:59AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the emerging leader of the $1.6 billion U.S. peripheral nerve repair market, announced financial results for the fourth quarter and full year ended December 31, 2013. Revenue for the quarter grew 46% to $3.0 million and for the year grew 42% to $10.9 million as compared to comparable periods.
AxoGen, Inc. to Present at Canaccord Genuity Musculoskeletal Conference
GlobeNewswire - Mon Mar 03, 6:03AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the only company completely focused on peripheral nerve repair, is scheduled to present at the 9th Annual Canaccord Genuity Musculoskeletal Conference on Tuesday, March 11, 2014 at 11:10am CT (12:10pm ET) at the Sheraton New Orleans Hotel.
AxoGen, Inc. to Report Fourth Quarter and Full Year 2013 Financial Results on March 6, 2014
GlobeNewswire - Wed Feb 12, 6:04AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the only company completely focused on peripheral nerve repair, will report results for the fourth quarter and full year ended December 31, 2013 on Thursday, March 6, 2014 after the market closes.
AxoGen, Inc. Announces Presentation of New Clinical Data For Avance(R) Nerve Graft
GlobeNewswire - Thu Feb 06, 6:03AM CST
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), the only company completely focused on peripheral nerve repair, today announced that new data from the CHANGE Study and the Ranger(R) Study was presented by study investigators at the recent combined annual meetings of the American Association for Hand Surgery (AAHS), American Society for Peripheral Nerve (ASPN) and American Society for Reconstructive Microsurgery (ASRM).
AxoGen, Inc. Gives Presentation on Nerve Repair Science at International Conference
GlobeNewswire - Fri Jan 24, 6:03AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the only medical products company completely focused on peripheral nerve repair, today announced the acceptance of a scientific presentation on nerve repair at the International Symposium on Peripheral Nerve Regeneration (ISPNR) 2014 Meeting. The symposium, being held in Torino, Italy, acts as a platform for presenting and discussing new developments in the field of nerve regeneration and tissue engineering and attracts clinicians and researchers from across the globe.
AxoGen, Inc. to Present at Noble Financial Capital Markets' Tenth Annual Equity Conference
GlobeNewswire - Tue Jan 21, 6:03AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the only medical products company completely focused on peripheral nerve repair, today announced that Greg Freitag, AxoGen's Chief Financial Officer and General Counsel, is scheduled to present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida on Wednesday, January 22, 2014 at 8:30 am ET.
Insureon CEO: Technology Investments Key to Acquisition Target Insurance Noodle
Fran Lysiak - AMBest - Fri Jan 10, 3:44PM CST
Insureon, an online commercial insurance broker and technology company, has agreed to acquire Insurance Noodle, the online wholesale broker and subsidiary of Willis Group Holdings.
Gerald Commissiong, CEO of Amarantus to Participate in Twitter Chat, "The Human Brain"
GlobeNewswire - Thu Jan 09, 2:58PM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that the Company's President and CEO, Gerald E. Commissiong will participate in a Twitter chat tonight at 9:00 PM ET on the topic, "The Human Brain."
AxoGen, Inc. to Sponsor "Current Concepts for Improving Nerve Repair Outcomes" at the American Association for Hand Surgery (AAHS) Annual Meeting
GlobeNewswire - Thu Jan 09, 6:02AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), the only regenerative medicine company completely focused on peripheral nerve repair, today announced that it will sponsor a lunch symposium and panel discussion at the combined annual meetings of the American Association for Hand Surgery (AAHS), American Society for Peripheral Nerve (ASPN) and American Society for Reconstructive Microsurgery (ASRM) taking place January 8-14, 2014 in Kauai, Hawaii.
AxoGen Receives Product Innovation Leadership Award from Frost & Sullivan
GlobeNewswire - Mon Jan 06, 1:32PM CST
via PRWEB - AxoGen, Inc. (NASDAQ:AXGN), the only regenerative medicine company completely focused on peripheral nerve repair, has been awarded the 2014 North American New Product Innovation Leadership Award for Peripheral Nerve Repair by the preeminent global research organization, Frost & Sullivan. The award is based on the findings of Frost & Sullivan's Best Practices Research Team which studied the nearly one million peripheral nerve injury repair procedures performed every year in the United States and recognized AxoGen for developing and commercializing the Avance(R) Nerve Graft.
Frost & Sullivan Applaud AxoGen's Proprietary Process for Producing Decellularized Nerve Allografts
PR Newswire Europe - Mon Jan 06, 6:45AM CST
-- AxoGen is the only regenerative medicine company that is completely focused on peripheral nerve repair
Nasdaq stocks posting largest volume increases
AP - Thu Jan 02, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
AxoGen (AXGN) in Focus: Stock Surges 25.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 8:46AM CST
AxoGen was a big mover last session, with shares rising over 25%.
